How Trump’s DEI Ban Will Affect Medical Research

Changes limiting programs, grants, and even the nature of studies are already underway at the NIH, NSF, FDA, CDC, and more.On President Trump’s first day in office, he signed an executive order to end what he calls “illegal and immoral discrimination programs,” referencing diversity, equity, and inclusion (DEI) in the federal government. The repercussions of this are already being felt across science agencies.Things are changing fast: Last week, a federal judge in Maryland temporarily blocked parts of the DEI purge from being carried out. At the same time, federal research agencies have already made changes. For example, the National Institutes of Health suddenly pulled a program that provides grants to PhD students from marginalized backgrounds, and has already canceled studies mid-project, like one on LGBTQ cancer patients. The National Science Foundation has begun reviewing active research science projects that may not comply with Trump’s executive orders. The Centers for Disease Control and Prevention took down resources for HIV prevention, LGBTQ+ health, contraception, and more—then partially restored them, as ordered by a judge. And the Food and Drug Administration pulled its guidance on the importance of having some diversity in clinical trials, like those to test drugs and medical devices.So, what does banning diversity, equity, and inclusion efforts mean for medical research? And what does it mean for our health?Host Flora Lichtman talks with Dr. Rachel Hardeman, director of the Center for Antiracism Research for Health Equity at the University of Minnesota in Minneapolis; and Dr. Melissa Simon, an ob-gyn at Northwestern Medicine, and director of the Center for Health Equity Transformation in Chicago.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

There are no comments yet.

Please log in to write the first comment.